TIP127 TroFuse-012: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab Vs Treatment of Physician’s Choice in Participants With Triple-Negative Breast Cancer who Received Neoadjuvant Therapy and Did Not Achieve
Publisher
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- CancerNetwork
- Region
- Global
- Scope
- discovery
- Published
- July 4, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: CancerNetwork
Scope: discovery
Related coverage
More related coverage
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 34 new drug applications...
Center for Scientific Review; Notice of Closed Meetings
Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for Information
The Office of the Assistant Secretary for Health (OASH or we) is opening a public docket to solicit...